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a  b  s  t  r  a  c  t
Acute kidney injury in the critically ill represents an independent risk factor of morbidity and
mortality in the short and long terms, with signiﬁcant economic impacts in terms of public
health costs. Currently its diagnosis is still based on the presence of oliguria and/or a gradual
increase in serum creatinine, which make the diagnosis a delayed event and to detriment
of  the so-called ‘therapeutic window’. The appearance of new biomarkers of acute kidney
injury could potentially improve this situation, contributing to the detection of ‘subclinical
acute kidney injury’, which could allow the precocious employment of multiple treatment
strategies in order to preserve kidney function. However these new biomarkers display sen-
sitive features that may threaten their full capacity of action, which focus speciﬁcally on
their additional contribution in the early approach of the situation, given the lack of speciﬁc
validated treatments for acute kidney injury. This review aims to analyze the strengths and
weaknesses of these new tools in the early management of acute kidney injury.
©  2016 Sociedad Espan˜ola de Nefrologı´a. Published by Elsevier Espan˜a, S.L.U. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
Biomarcadores  en  la  lesión  renal  aguda:  ¿  paradigma  o  evidencia?
alabras clave:
r  e  s  u  m  e  n
La lesión renal aguda en los pacientes críticos representa un factor de riesgo independiente
iomarcadores de  la morbilidad y la mortalidad a corto y a largo plazo, con un tremendo impacto económico
s en salud pública. Por el momento, el diagnóstico de la lesión renalesión renal aguda en  cuanto a los costeaguda sigue basándose en la presencia de oliguria o en un aumento gradual de la creatinina
sérica, hecho que retrasa el diagnóstico, en detrimento de la llamada «ventana terapéutica».
La  aparición de nuevos biomarcadores de lesión renal aguda podría mejorar esta situación y
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contribuir a la detección de la «lesión renal aguda subclínica», lo que permitiría el uso precoz
de  múltiples estrategias de tratamiento con el objetivo de preservar la funcionalidad renal.
No  obstante, los nuevos biomarcadores presentan características que podrían vulnerar su
capacidad de acción, centrada concretamente en aportar un valor an˜adido al abordaje precoz
de  la enfermedad, dada la falta de tratamientos especíﬁcos validados para la lesión renal
aguda. Esta revisión tiene como objetivo analizar los puntos fuertes y débiles de esta nueva
herramienta para el diagnóstico temprano de la lesión renal aguda.
©  2016 Sociedad Espan˜ola de Nefrologı´a. Publicado por Elsevier Espan˜a, S.L.U. Este es un
artı´culo Open Access bajo la licencia CC BY-NC-ND (http://creativecommons.org/licenses/Introduction
In the article “Dissent, Dogmatism and Belief Polarization”,1
published in The Journal of Philosophy, Thomas Kelly refers to
a phenomenon called “belief polarization” by which exposure
to the same evidence, far from bringing those who have differ-
ent opinions closer, usually makes the disagreement between
them become more  pronounced: we  are more  demanding with
anything that contradicts our belief and more  permissive with
what favors our own point of view.
This phenomenon may partly explain our acceptance or
rejection of the use of new biomarkers in the diagnosis of acute
kidney injury (AKI).
In 2005, the American Society of Nephrology Renal
Research Report (ASNRRR) assigned the highest research
priority to the discovery and standardization of new AKI
biomarkers.2
AKI in critically ill patients is an independent risk fac-
tor that increases morbidity and mortality in the short and
long term, with a tremendous ﬁnancial impact in terms of
health costs.3 AKI is also a gateway to chronic kidney disease
(CKD).4 It is noteworthy that, after an AKI episode, 7.8 of every
100 patients/year develop CKD and 4.9 per 100 patients/year
will develop advanced chronic kidney disease.5
There has been numerous preventive or curative strate-
gies for AKI that have been either ineffective or insufﬁciently
validated to be routinely recommended.4
The most important risk factor for AKI is the pre-existing
CKD, which increases its risk up to 10 times.6,7,8
Some processes, such as endothelial dysfunction,9 myocar-
dial remodeling,10 epigenetic factors11 and increased oxida-
tive stress,12 are factors that could explain the increased risk
of morbidity and mortality that persists long after the AKI
episode.
Another reason that may explain the negative outcome of
AKI patients is the late recognition of kidney injury leading to
delayed interventions.
We  must bear in mind that the diagnosis of AKI is based on
indirect markers of kidney damage, that are not very sensi-
tive or speciﬁc, to the detriment of the so-called “therapeutic
window”.4
In this context, there are various limitations of serum cre-
atinine (sCr): sCr comes into play as a functional marker
when more  than 50% of the glomerular ﬁltration rate has
been lost and is only useful after a stationary state has been
reached. The latter may differ over time, sometimes up to 48 h,by-nc-nd/4.0/).
especially in patients in intensive care units (ICU).12 On the
other hand, the excretion of creatinine does not depend on the
load ﬁltered solely by the glomeruli, but also on that secreted
by the kidney tubules, which normally varies from 5 to 20%
of total excretion, and may increase to 50% as a compen-
satory mechanism when the glomerular ﬁltration rate (GFR)
decreases.13 Also, even if there were genuinely a fall in GFR, the
sCr might not increase or increase late as a result of recruit-
ment of the renal functional reserve; also the sCr could be
“diluted” as a result of a profuse positive balance, which is fre-
quently observed after resuscitation maneuvers, especially in
patients in the ICU.14 Finally, the eGFR seems to overestimate
renal function in patients admitted to ICU during a long period
of time. This was well demonstrated in a secondary analysis
of the EPANIC study, in which 757 patients participated and
which showed that a reduction in production of sCr positively
correlated with the length of stay in the ICU, probably due to
loss of muscle mass.15
The other parameter of AKI is oliguria, which is neither
sensitive nor speciﬁc, since it could occur as a result of a kidney
injury, but may also reﬂect an adaptive physiological response
to either intracellular dehydration or hypovolemia.16 Only a
small proportion of oliguric patients in the ICU have in fact a
sustained fall in GFR which is reﬂected in an increase in sCr.16
Similarly, Mandelbaum et al.17 showed that only pronounced
(<0.3 mL/kg/h) or prolonged (>12 h) episodes of oliguria were
associated with the need to start renal replacement therapy
(RRT) or with increased hospital mortality.
The most recent biomarkers promise: to identify early
patients at risk of AKI; to diagnose AKI earlier than with other
conventional tests; to indicate the need to initiate RRT and
also predict the risk for progression to CKD.18,19 The objective
is to accomplish more  timely interventions the more  favorable
outcomes in patients with AKI. The availability of these new
biomarkers and the evaluation of simultaneous combinations
of functional and tissue damage biomarkers may help strat-
ify patients into 4 subgroups: no change in biomarkers, only
changes in functional biomarkers, only changes in biomark-
ers of tissue injury, or changes in the 2, functional and injury
biomarkers (Fig. 1).
This new approach allows the identiﬁcation of a new cate-
gory of patients with AKI, called “Subclinical AKI”, represented
by an increase in markers of tissue injury without a simul-
taneous reduction of kidney function. Based on this new
conceptual framework, a modiﬁcation of the KDIGO criteria
recommend the incorporation of kidney injury markers, to sCr,
GFR and diuresis (Fig. 2).20
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No damage
No functional
change
Functional
change
Damage present
Resolution
Damage without
loss of function
No functional changes
or damage
Loss of function
without damage
Damage with loss of
function
Progression
Fig. 1 – Functional use of the new acute kidney injury
biomarkers. From:  Acute Dialysis Quality Initiative (ADQI).
Available at: http://www.ADQI.org [accessed 10.01.13].
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Fig. 3 – Source of acute kidney injury biomarkers. g-GT,
g-glutamyl transpeptidase; GST, glutathione S-transferase;
HGF, hepatocyte growth factor; IGFBP-7, insulin-like growth
factor-binding protein 7; IL-18, interleukin 18; KIM-1,
kidney injury molecule; L-FABP, liver-type fatty
acid-binding protein; NAG, N-acetyl-d-glucosaminidase;
NGAL, neutrophil gelatinase-associated lipocalin; RBP,
retinol-binding protein; TIMP-2, tissue inhibitor ofThis new approach has been recognized and recently
ncorporated to the deﬁnition of AKI in Australia and New
ealand regional practice guides, without clarifying what kind
f biomarker to use or its cutoff value.21
New AKI biomarkers vary in their source, in their func-
ion, in their distribution and in the time of their release after
idney injury (Fig. 3).
Most evidence has focused on neutrophil gelatinase-
ssociated lipocalin (NGAL), either urinary or plasmatic,
idney injury molecule (KIM-1), interleukin 18 (IL-18), N-
cetyl-d-glucosaminidase (NAG), cystatin C (Cys-C), tissue
nhibitor of metalloproteinases (TIMP-2) and insulin-like
rowth factor-binding protein 7 (IGFBP-7).22
In homogeneous populations of patients such as those
ndergoing cardiopulmonary bypass surgery, biomarkers such
s NGAL, KIM-1, Cys-C and IL-18 appear to be an attrac-
ive instrument to detect AKI before changes in sCr are
23–27bserved. However, in heterogeneous populations with
ifferent pathologies, such as ICU patients or patients from
he emergency room, the individual performance of these
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ig. 2 – New criteria for the diagnosis of acute kidney
njury. From:  Acute Dialysis Quality Initiative (ADQI).
vailable at: http://www.ADQI.org [accessed 10.01.13].metalloproteinases.38
biomarkers is markedly lower.23,28 The performance of most
biomarkers is variable and depends on the underlying pathol-
ogy affecting the patient, the ethiology of AKI, clinical
aspects, associated comorbidities and the timing of the
measurements.22
Some biomarkers, as for example NGAL, reﬂect the sever-
ity of the triggering disease rather than being speciﬁc to the
kidney injury.29–31
NGAL is a gelatinase-associated human neutrophil that
exists as a 25 kDa monomer, as a 45 kDa  homodimer
and as a gelatinase it conjugates with a 135 kDa het-
erodimeric conformation.32 Monomeric and heterodimeric
forms are mainly produced by tubule epithelial cells, while the
homodimeric form occurs mainly in activated neutrophils.32
Circulating NGAL ﬁlters through the glomerular barrier and
is fully reabsorbed by megalin-mediated endocytosis at nor-
mal  proximal tubule cells level. There are commercial kits to
measure uNGAL (urinary NGAL) or pNGAL (plasmatic NGAL).
Under stable conditions, plasma and urine concentrations are
around 20 ng/mL. The marker increases 2–4 h after the kidney
damage occurs. The NGAL has been associated with a prob-
able kidney protective effect, since it is released by nephron
segments where they can form a complex with siderophores
that binds to iron; thus, the iron released by the damaged tubu-
lar cells is chelated which prevents the formation of hydroxyl
radicals and superoxide anions.
NGAL levels also rise in experimental sepsis and sys-
temic inﬂammation models, suggesting that the release into
the urinary system is the response of the kidney to a sys-
temic infection or to the local urogenital infection.33 This
is an important limitation to the use of NGAL, especially in
terms of its diagnostic performance during AKI  associated to
sepsis.32Cystatin C is a 13 kDa protein produced by all nucleated
cells that is released into the plasma at a constant rate, regard-
less of sex, race, muscle mass and hydration level. It circulates
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in plasma and it is not bound to any protein, is freely ﬁltered
through the glomerulus and is fully reabsorbed by megalin-
mediated endocytosis at proximal tubule cells level.
Diabetes, high doses of corticosteroids, hypertriglyc-
eridemia, hyperbilirubinemia or rheumatoid factor may affect
the analysis of Cys-C.33 It is not secreted by tubule cells and
is not detectable in the urine of healthy subjects. Conse-
quently, increased urinary Cys-C values during AKI reﬂects
decreased reabsorption at proximal tubule level.33 Urine Cys-
C (u Cys-C) appears as an earlier and more  sensitive marker
of AKI as compared with pCys-C (plasma). However, the con-
centration of pCys-C is mainly correlated with GFR, even in
a range where sCr is not able to detect early changes in
GFR (60–90 mL/min). It appears in urine 12–24 h after kidney
damage.
KIM-1 is a cell membrane glycoprotein whose mRNA  levels
increase more  than any other gene after kidney injury. The
90 kDa soluble ectodomain is part of the dependent metal-
loproteinase complexes and it is released into the tubule by
epithelial cells making it readily detectable in urine. During
kidney injury, KIM-1 can facilitate remodeling of the injured
epithelium. It appears 12 to 24 h after kidney damage.
IL-18 is an 18 kDa proinﬂammatory cytokine produced
mainly by activated neutrophils, mononuclear cells,
macrophages and non-immune cells, including the prox-
imal tubule cells. It is an important ischemic AKI mediator.33
It can be found in urine and plasma. It appears 6–24 h after
kidney damage.
NAG is a large-sized protein (approximately 140 kDa) that
originates in the lysosomes of proximal tubule cells. Its high
molecular weight prevents glomerular ﬁltration and, there-
fore, it is unlikely that high urinary levels come from a
non-renal source. NAG is correlated with histological evi-
dence of renal proximal tubule damage. Urinary NAG at
ICU admission correlates well with results in critically ill
patients. However, urinary NAG has been shown to be a
sensitive marker of tubular injury, and its speciﬁcity can
be reduced by a low threshold for the release of the
tubular enzyme. False positive values have been reported
during diabetes, rheumatoid arthritis and hyperthyroidism.33
The increase in urine is observed 12 h after kidney
damage.
In this regard, recently the Food and Drug Administration
(FDA) approved the marketing of the Nephrocheck Test and
Astute 140 Meter (Astute Medical Inc., San Diego, CA, USA), a
rapid test that quantitatively measures TIMP-2 and IGFBP-734
cell cycle arrest biomarkers, which block the effect of cyclD-
CDK4 and CyclE-CDK2 in cell cycle promotion, making them
ideal G1 cell cycle arrest markers. The Astute 140 meter auto-
matically multiplies the concentrations of the 2 biomarkers
together and divides this product by 1000, reporting a sin-
gle test result with units in (ng/ml)2/1000. In clinical practice,
after AKI there is activation of cell division and cell prolifer-
ation in order to repopulate the denuded tubular epithelium.
Early cell cycle arrest in G0/G1 could protect the kidney from
further damage, by blocking DNA damage and caspase 3/7 acti-
vation, thereby limiting the extent of damage and avoiding
a potentially dangerous maladaptive process caused by poor
repair. These phenomena occur 24–48 h before the increase in
sCr which occurs after a signiﬁcant drop in the GFR, and the;3 6(4):339–346
early detection could undoubtedly facilitate new therapeutic
and protective strategies, as suggested by the latest KDIGO
guidelines.35
The combination of these 2 biomarkers seems to be highly
predictive of patients who ultimately develop moderate to
severe AKI within the next 12–24 h. The performance of
these markers compared to other markers has an area under
curve (AUC) with a conﬁdence index (CI) 95% greater than
0.8, especially when combined. The application of MAKE30
(which predicts adverse kidney events within 30 days, such
as death, the need for RRT or duplication of sCr) increases
substantially with the use of TIMP-2/IGFBP-7 when the val-
ues are >0.3 (ng/ml)2/1000 and were doubled with values
>2.0 (ng/ml)2/1000.36,37
The international multicenter Sapphire study, conducted
in 728 critically ill patients, showed that the increase in
performance by the combination of these biomarkers was AKI-
speciﬁc (i.e., it is not caused by other comorbidities such as
sepsis or CKD) and provided a strong signal as a “kidney alarm”
to identify patients who are at imminent risk of developing
AKI.36,37 These urinary biomarkers are believed to increase in
response to the kidney tubule cell stress or early injury asso-
ciated with factors known to cause AKI. The primary clinical
cutoff value of >0.3 (ng/ml)2/1000 for the combination of the
2 biomarkers derives from the Sapphire study data, which
was veriﬁed in the Opal study, on a cohort of 153 critically
ill patients.37
This cutoff point was selected for its high sensitivity (92%)
to detect moderate to severe AKI within the next 12 h; this is to
identify patients at high risk of AKI in routine clinical practice
so recommended treatment can be started early following the
KDIGO guidelines for high-risk patients.20
A second cutoff point was sought with high speciﬁcity
>2.0 (ng/ml)2/1000 in order to identify the subset of patients
who are at greater risk of AKI and, therefore, could bene-
ﬁt from more  aggressive interventions. These cutoff points
between 0.3 and 2.0 (ng/ml)2/1000 were subsequently val-
idated in a study involving 23 sites and 408 critically ill
patients in the United States (Topaz study) and whose primary
objective was to identify patients with moderate to severe
AKI.38
The most notable properties of these urinary biomark-
ers, and for which they were selected from more  than
300 biomarkers, include: excellent performance, and having
been validated, in heterogeneous populations with various
pathologies (sepsis, shock, major surgery and trauma) in 3
different cohorts of critically ill patients.37 Also, recent pub-
lications highlight the ability of these biomarkers in the
ICU environment to identify patients with AKI who  are at
increased risk of mortality or need for RRT in the next
9 months.39
The combination of two or more  biomarkers an other clini-
cal data is an attractive strategy to reﬁne current diagnostic
capacity. Despite great advances in this ﬁeld, it should be
noted that there are different methodological problems in AKI
biomarker research; including the following:(1) The performance of the new biomarkers was judged by
comparison with sCr and oliguria, in the absence of a “gold
standard” in current AKI diagnosis. These 2 markers, sCr
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and oliguria, as already mentioned, are affected by exter-
nal factors.
2) Studies vary in the cutoff points chosen to set thresholds
for positive and negative predictive AKI-related events.
3) There is uncertainty about the exact laboratory method,
test platform and sampling conditions, and whether
biomarker levels should be normalized in relation to uri-
nary creatinine.
4) Like creatinine, several novel AKI biomarkers are them-
selves not speciﬁc for kidney pathologies and can be
inﬂuenced by common comorbid conditions, such as sep-
sis.
5) Most of the biomarkers show a reﬂect a dynamic pattern of
molecular and cellular events occurring during the clini-
cal or subclinical AKI phase. It is therefore likely that a
panel of different biomarkers and multiple measurements
combined is better than a single test.
iomarkers:  paradigm
he general concept is that in AKI at least a part of the kidney
issue can be protected by early detection and intervention.
his may be especially true in the early stages of the renal
njury, which would prevent further damage and would pre-
erve renal functional reserve.
According to KDIGO standards small increases in sCr are
eeded to reach AKI stage i and this reﬂect a profound and
rolonged decrease in GFR. There is a need for AKI biomark-
rs that rapidly detect changes that allow the identiﬁcation of
ubclinical kidney injuries.4
Early detection of such patients would allow a stratiﬁcation
y risk according to increased biomarkers or a combination
f them that could ultimately help in validating preventive
trategies and future therapies. Beyond early diagnosis and
isk stratiﬁcation, biomarkers have improved our understand-
ng of the pathophysiological mechanisms associated with
KI. They have helped to challenge the up to now obsolete
ichotomy between the so-called “prerenal AKI” and “renal
KI” (misnamed “acute tubular necrosis”).40 Patients formally
dentiﬁed as “prerenal AKI” or “transient AKI” and/or with “low
rinary sodium excretion” also have evidence of tubular injury
r damage, so that the current deﬁnition has become obsolete,
specially at the subcellular and molecular level.40
This change in our global vision of the pathophysiologi-
al mechanism of AKI will without doubt in the near future
elp us in the therapeutic design of alternative strategies
nd in focusing on patients most likely to beneﬁt from these
trategies with an individualized approach driven by the
iomarkers, a diagnosis and personalized treatment.40,41
The assessment of the kidney prognosis, and speciﬁcally
idney recovery after AKI, are issues that have recently arisen
ith direct implications for all health systems. The objective is
revention of progression to CKD, either by reducing the level
f the injury or facilitating the healing and recovery of the
amaged kidney and the control of risk factors. The injury,
owever, reduces the functioning renal mass and functional
eserve. This process is key for the development of CKD.(4):339–346 343
The validation of biomarkers is insufﬁcient to recommend
its clinical use until now,13,16,17,42 and some results have even
been disappointing.29,43
One of the reasons for these negative results may be based
in erroneous population of patients studied. The type of ICU
patients who may require the use of these biomarkers is still
unknown. The population of interest could theoretically inﬂu-
ence the diagnostic performance of the tests,44 as well as their
clinical relevance.
Future efforts in this area should probably focus on eval-
uating the best current biomarkers in well-deﬁned groups
with high pretest likelihood of AKI and in contexts in which
biomarkers can alter the clinical decision making.
Biomarkers:  evidence
It is important to identify patients at high risk of AKI, espe-
cially if this provides an opportunity to intervene. In the
speciﬁc case of AKI, recommended preventive strategies cur-
rently include the optimization of the hemodynamic status,
volume status and avoiding nephrotoxic drugs, contrast media
and/or starches.4 It could easily be argued that this should be
done in any critical patient, regardless of whether or not the
patient is at high risk of developing AKI, and therefore the
information that a biomarker can provide us may be redun-
dant.
Ideally, the test to identify high risk patients should be as
reliable as possible to avoid false negative and false positive
results. Based on the experience from other clinical areas, the
unselected use of biomarkers such as prostate speciﬁc anti-
gen (PSA) or d-dimer in an unselected population produces
a high number of false positive results and can potentially
lead to harmful and unnecessary interventions.45 The perfor-
mance of most biomarkers for AKI is better in selected groups
of patients at high risk of AKI. For example, IGFBP7 and TIMP-
2 that were evaluated and validated for use by the FDA in
critically ill patients in ICU units.18,39
Can  the  new  biomarkers  diagnose  acute  kidney  injury
earlier  than  traditional  tests?
Several biomarkers have been shown to indicate the onset
of AKI before increases of sCr occur (subclinical AKI). The
results are more  solid in pediatric cohorts without comor-
bidities suffering from a disease with a deﬁned onset of
AKI, such as for example in children after heart surgery.39
In more  heterogeneous populations, where no occurrence
of kidney injury is known (i.e., patients with septic shock),
the performance of some biomarkers for early detection
of AKI was equivalent to the clinical assessment and
standard laboratory measurements and was not signiﬁcantly
better.29,30,40
It is generally assumed that an earlier diagnosis of AKI
would translate directly into an earlier RRT and a better out-
come for the patient. Unfortunately, there is currently no
evidence that this actually happens, since there is no speciﬁc
treatment for AKI.
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Can  the  new  acute  kidney  injury  biomarkers  identify
patients  who  need  kidney  replacement  therapy?
Prediction of whether patients will need RRT is similar to
predicting who will develop AKI. To date, there are no interven-
tions beyond treatment of the underlying disease, attention
to detail and good health care that prevent progression of AKI
or induce recovery. Although it may seem appealing to know
which patient will need RRT, it is very unlikely that this infor-
mation will change clinical practice, especially since there
is no evidence that early RRT is more  beneﬁcial.46 However,
knowing whether a patient with RRT has recovered kidney
function can be very useful.
Does  the  use  of  the  new  acute  kidney  injury  biomarkers
improve  patient  outcomes?
The efﬁcacy of a speciﬁc intervention based on increased
biomarkers has not been demonstrated. The only intervention
study using biomarkers to guide treatment was negative.41
Therefore, the claim that the use of biomarkers beneﬁts
patients and improves the outcome remains unproven.
When  should  acute  kidney  injury  biomarkers  be
measured?
It has been difﬁcult to identify which patients would beneﬁt
more  with the use of the biomarkers in situations in which the
outcome already seems predictable based on standard param-
eters, such as clinical diagnosis and oliguria. Clearly in this
situation, there is little additional beneﬁt, just as with an appli-
cation in patients with low risk of AKI, which leads to a useless
use of the biomarkers, with an unnecessary increase in health
care costs.
Conclusion
It has been suggested that AKI should be called “kidney
attack”,46 in order to draw an analogy with a heart attack, and
that a “kidney troponin” could be used to detect AKI early,
as in acute myocardial infarction (AMI). Probably the analogy
between the 2 conditions crumbles when potential interven-
tions are considered. AMI  has speciﬁc treatments. Yet even
if a reliable biomarker showed AKI early, there would be no
currently speciﬁc treatments that could be offered for the
treatment of tubular ischemia or septic nephropathy.
While the results regarding the ability of biomarkers to
improve the predictive value of AKI47–50 are contradictory and
have not yet made the transition to clinical routine, recent
publications of the Acute Dialysis Quality Initiative (ADQI)20
should be noted, which promote the search for early identiﬁ-
cation of damage or risk of AKI, especially in those patients
in whom sCr is negative and biomarkers are positive; the
promotion is based on the potential for the latter to trans-
form the manner of diagnosis and treatment of AKI. However,
these same recommendations, together with the KDIGO AKI
guidelines,4 clearly state that so far sCr and diuresis repre-
sent the best markers with clinical applicability of AKI for use
in diagnosis and monitoring. Thus we  believe that the “belief;3 6(4):339–346
polarization” must be oriented to the evidence, based on the
development of new paradigms and use of new biomarkers in
AKI.
Key  phrases
• Acute kidney injury (AKI) in critically ill patients is an inde-
pendent risk factor that increases morbidity and mortality
in the short and long term, with a tremendous ﬁnancial
impact in terms of health costs. AKI is also a ﬁrst step toward
chronic kidney disease (CKD).
• The diagnosis of AKI is based on indirect markers of kidney
damage (sCr and diuresis), which are very insensitive and
unspeciﬁc, to the detriment of the so-called “therapeutic
window”.
• The new AKI biomarkers promise early identiﬁcation of
patients at risk of AKI, early diagnosis of AKI, indicating the
need to initiate RRT and predicting the risk of progression
to CKD.
• The ADQI proposes 4 possible combinations between
functional and tissue damage biomarkers: no change in
biomarkers, only changes in functional biomarkers, only
changes in damage biomarkers, or changes in the 2
biomarkers, functional and damage.
• The FDA approved the use of TIMP-2 and IGFBP-7 cell cycle
arrest biomarkers in a heterogeneous population such as
the ICU population, which appear to be highly predictive of
the development of moderate to severe AKI in the following
12–24 h.
• Future efforts in this area should probably focus on evaluat-
ing the best current biomarkers in well-deﬁned groups with
high likelihood of AKI and in contexts in which biomarkers
can alter clinical decision making.
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